Copyright: ©Author(s) 2026.
World J Transplant. Jun 18, 2026; 16(2): 118450
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.118450
Published online Jun 18, 2026. doi: 10.5500/wjt.v16.i2.118450
Table 6 Frequency (and percentage) of key adverse clinical outcomes observed within each immunologic risk cluster, n (%)
| Cluster | Acute rejection | Graft loss | Delayed graft function | Mortality |
| High risk cluster | 4 (6.9) | 4 (6.9) | 2 (3.4) | 3 (5.2) |
| Intermediate risk | 0 (0.0) | 2 (5.9) | 2 (5.9) | 2 (5.9) |
| Low risk cluster | 1 (5.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
- Citation: Al-Qurashi SH, Khalil MAM, Mahmood HHK, Alsharif MM, Alqurashi YF, Alghamdi L, Al-Ghamdi RA, Alsaedi ZA, Cruz AJD, Aboasamh GA, Sadagah NM. Immunologic clustering of donor-specific antibodies and clinical outcomes in kidney transplant recipients. World J Transplant 2026; 16(2): 118450
- URL: https://www.wjgnet.com/2220-3230/full/v16/i2/118450.htm
- DOI: https://dx.doi.org/10.5500/wjt.v16.i2.118450